These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16449540)

  • 21. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2015; 18(12):1050-9. PubMed ID: 26201252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients.
    Tanzi MG; Undre N; Keirns J; Fitzsimmons WE; Brown M; First MR
    Clin Transplant; 2016 Aug; 30(8):901-11. PubMed ID: 27220013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study.
    Dumortier J; Duvoux C; Dubel L; Bazin F; Houssel-Debry P
    Ann Transplant; 2019 Aug; 24():506-516. PubMed ID: 31451681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcineurin inhibitors in heart transplantation.
    Crespo-Leiro MG
    Transplant Proc; 2005 Nov; 37(9):4018-20. PubMed ID: 16386614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
    Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients.
    Dansirikul C; Staatz CE; Duffull SB; Taylor PJ; Lynch SV; Tett SE
    J Clin Pharm Ther; 2006 Feb; 31(1):17-25. PubMed ID: 16476116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis.
    Abecassis MM; Seifeldin R; Riordan ME
    Transplant Proc; 2008 Jun; 40(5):1443-5. PubMed ID: 18589126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence.
    Venkat VL; Nick TG; Wang Y; Bucuvalas JC
    Pediatr Transplant; 2008 Feb; 12(1):67-72. PubMed ID: 18186891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period.
    Blanchet B; Duvoux C; Costentin CE; Barrault C; Ghaleh B; Salvat A; Jouault H; Astier A; Tod M; Hulin A
    Ther Drug Monit; 2008 Aug; 30(4):412-8. PubMed ID: 18641556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.